ALX Oncology (NASDAQ: ALXO) net income
ALX Oncology reported a net loss of $101.7m for fiscal 2025; in fiscal 2024 it reported a net loss of $134.9m. Earnings per share were −$1.90.
ALX Oncology's best year of the last 7 was fiscal 2019. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$101.7m | — | — | −$1.90 |
| 2024 | −$134.9m | — | — | −$2.58 |
| 2023 | −$160.8m | — | — | −$3.74 |
| 2022 | −$123.5m | — | — | −$3.03 |
| 2021 | −$83.5m | — | — | −$2.07 |
| 2020 | −$45.7m | — | −3,869.7% | −$2.76 |
| 2019 | −$19.2m | — | −401.2% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
ALX Oncology net income compared with its sector
By net income for its latest fiscal year, ALX Oncology ranks 335th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 333rd | Lexeo Therapeutics | −$100.0m | — |
| 334th | Tango Therapeutics | −$101.6m | −162.9% |
| 335th | ALX Oncology | −$101.7m | — |
| 336th | Perspective Therapeutics | −$103.1m | — |
| 337th | Schrodinger | −$103.3m | −40.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of ALX Oncology
- How much did ALX Oncology earn in fiscal 2025?
- ALX Oncology reported a net loss of $101.7m for fiscal 2025. In fiscal 2024 it reported a net loss of $134.9m.
- What are the earnings per share of ALX Oncology?
- They were −$1.90 in fiscal 2025, compared with −$2.58 in fiscal 2024.
- Where does ALX Oncology rank in its sector by net income?
- It ranks 335th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for ALX Oncology come from?
- From the annual report (Form 10-K) that ALX Oncology files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that ALX Oncology files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on ALX Oncology: the ALX Oncology page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.